Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 36% Improvement Relative Risk c19hcq.org Lavilla Olleros et al. HCQ for COVID-19 LATE Is late treatment with HCQ beneficial for COVID-19? Retrospective 14,921 patients in Spain Lower mortality with HCQ (p<0.000001) Lavilla Olleros et al., PLOS ONE, doi:10.1371/journal.pone.0261711 Favors HCQ Favors control
Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19
Lavilla Olleros et al., PLOS ONE, doi:10.1371/journal.pone.0261711
Lavilla Olleros et al., Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19, PLOS ONE, doi:10.1371/journal.pone.0261711
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 14,921 hospitalized patients in Spain, showing lower mortality with HCQ treatment.
risk of death, 36.2% lower, RR 0.64, p < 0.001, treatment 2,285 of 12,772 (17.9%), control 774 of 2,149 (36.0%), NNT 5.5, adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lavilla Olleros et al., 21 Jan 2022, retrospective, Spain, peer-reviewed, 22 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: PLOS ONE RESEARCH ARTICLE Use of glucocorticoids megadoses in SARSCoV-2 infection in a spanish registry: SEMICOVID-19 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 OPEN ACCESS Citation: Lavilla Olleros C, Ausı́n Garcı́a C, Bendala Estrada AD, Muñoz A, Wikman Jogersen PE, Fernández Cruz A, et al. (2022) Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19. PLoS ONE 17(1): e0261711. https://doi.org/ 10.1371/journal.pone.0261711 Editor: Aleksandar R. Zivkovic, Heidelberg University Hospital, GERMANY Received: July 4, 2021 Accepted: December 7, 2021 Cristina Lavilla Olleros ID1☯*, Cristina Ausı́n Garcı́a1☯, Alejandro David Bendala Estrada1☯, Ana Muñoz2, Philip Erick Wikman Jogersen ID3, Ana Fernández Cruz4, Vicente Giner Galvañ3, Juan Antonio Vargas4, José Miguel Seguı́ Ripoll3, Manuel Rubio-Rivas5, Rodrigo Miranda Godoy6, Luis Mérida Rodrigo7, Eva Fonseca Aizpuru ID8, Francisco Arnalich Fernández9, Arturo Artero10, Jose Loureiro Amigo11, Gema Marı́a Garcı́a Garcı́a ID12, Luis Corral Gudino ID13, Jose Jiménez Torres ID14, JoséManuel Casas-Rojo15‡, Jesús Millán Núñez-Cortés1‡, On behalf of the SEMI-COVID-19 Network¶ 1 General Internal Medicine Department, Hospital Universitario Gregorio Marañón, Madrid, Spain, 2 General Internal Medicine Department, Infanta Cristina Hospital: Hospital Universitario Infanta 2 Cristina, ParlaMadrid, Spain, 3 General Internal Medicine Department, Hospital Universitario San Juan de Alicante, San Juan de Alicante-Alicante, Spain, 4 General Internal Medicine Department, Hospital Universitario Puerta de Hierro, Madrid, Spain, 5 General Internal Medicine Department, H. Univ. de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain, 6 General Internal Medicine Department, 12th of October University Hospital: Hospital Universitario 12 de Octubre, Madrid, Spain, 7 General Internal Medicine Department, Hospital Costa del Sol, Málaga, Spain, 8 General Internal Medicine Department, Hospital de Cabueñes: Hospital de Cabuenes, Gijón, Spain, 9 General Internal Medicine Department, La Paz University Hospital: Hospital Universitario La Paz, Madrid, Spain, 10 General Internal Medicine Department, Hospital Universitario Dr Peset: Hospital Universitario Doctor Peset, Valencia, Spain, 11 General Internal Medicine Department, Hospital de Sant Joan Despı́ Moisès Broggi: Hospital de Sant Joan Despi Moises Broggi, Barcelona, Spain, 12 General Internal Medicine Department, University Hospital Complex Badajoz: Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 13 Hospital Universitario Rio Ortega, Valladolid, Spain, 14 General Internal Medicine Department, Hospital Reina Sofı́a: Hospital Reina Sofia, Córdoba, Madrid, Spain, 15 General Internal Medicine Department, Infanta Cristina Hospital: Hospital Universitario Infanta Cristina, Parla-Madrid, Spain ☯ These authors contributed equally to this work. ‡ These authors also contributed equally to this work. ¶ Membership of the SEMI-COVID-19 Network is provided in the Acknowledgments. * cristinalavillaolleros@gmail.com Published: January 21, 2022 Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: https://doi.org/10.1371/journal.pone.0261711 Copyright: © 2022 Lavilla Olleros et..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit